ACRV - Acrivon Therapeutics, Inc. Common Stock News

Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Ph

Favorable, differentiated safety profile and durable single-agent clinical activity, including in he

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Ex

Favorable, differentiated safety profile and durable single-agent clinical activity, including in he

Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At A

Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and

Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1

seekingalpha.com

Acrivon Therapeutics: Priced For Failure, Built For Precision

Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform

Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit

WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon

Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the ana

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinic

The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous inter

Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a cl

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and AC

Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acriv

Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% – Still a Buy?

Shares of Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) were up 3.2% on Monday. The st

Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)

Acrivon Therapeutics (NASDAQ: ACRV - Get Free Report) and Oasmia Pharmaceutical (OTCMKTS:OASMY - Get

Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the ana

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business

Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overa

Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical syn

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Stro

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical syn

zacks.com

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why

Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Canc

Acrivon Therapeutics (NASDAQ: ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focu

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivo

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the

Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Int

Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to cond

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update

Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) saw a large decrease in short interest i

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynec

Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farbe

Acrivon Therapeutics (NASDAQ:ACRV) CFO Acquires $15,014.40 in Stock

Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) CFO Adam Levy purchased 8,832 shares of

Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8

Piper Sandler analyst Edward Tenthoff maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overwei

Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls

Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, a

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

12 Health Care Stocks Moving In Thursday's Intraday Session

Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings

Market-Moving News for January 8th

ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Acce

Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial Clinical Data From ACR-231

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a cl

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Tuesday's Intraday Session

Acrivon Therapeutics to Release New Cancer Drug Data on Jan. 8

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a cl

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Acrivon Therapeutics Said It Will Be Providing ACR-368 and ACR-2316 Clinical Data And Other Updates

Topics will include:Updated interim ACR-368 clinical data from the ongoing registrational-intent Pha

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a

Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.47) per share which beat the ana

12 Health Care Stocks Moving In Monday's Pre-Market Session

Acrivon Therapeutics To Deliver Three Presentations At The AACR-NCI-EORTC Highlighting Advances From

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein sig

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's After-Market Session

Oppenheimer Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $8

Oppenheimer analyst Matthew Biegler maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperfor

Acrivon Therapeutics Q2 EPS $(0.55) Beats $(0.58) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.55) per share which beat the ana